Eslam M, George J
eGastroenterology. 2025; 1(2):e100019.
PMID: 39943998
PMC: 11770426.
DOI: 10.1136/egastro-2023-100019.
Zhang Q, Liu Z, Zhang J, Yang S, Liu L
Sci Rep. 2025; 15(1):4566.
PMID: 39915562
PMC: 11802835.
DOI: 10.1038/s41598-024-84917-9.
Sun Y, Miao X, Hu M, Xie X, Liu S, Song Z
Sci Rep. 2025; 15(1):4455.
PMID: 39910118
PMC: 11799198.
DOI: 10.1038/s41598-025-88000-9.
Zheng S, Hua T, Yin G, Zhang W, Wang X, Qi L
Front Endocrinol (Lausanne). 2025; 15:1406065.
PMID: 39906038
PMC: 11790460.
DOI: 10.3389/fendo.2024.1406065.
Pirahesh K, Zarrinnia A, Nikniaz L, Nikniaz Z
Prev Med Rep. 2025; 50:102968.
PMID: 39897736
PMC: 11783128.
DOI: 10.1016/j.pmedr.2025.102968.
Comparative application of MAFLD and MASLD diagnostic criteria on NAFLD patients: insights from a single-center cohort.
Elsabaawy M, Naguib M, Abuamer A, Shaban A
Clin Exp Med. 2025; 25(1):36.
PMID: 39808219
PMC: 11732950.
DOI: 10.1007/s10238-024-01553-3.
Exploring the knowledge and attitudes towards metabolic dysfunction associated fatty liver disease (MAFLD): Validation and correlations of MAFLD-knowledge questionnaire and MAFLD-attitude questionnaire.
Al Tawil S, Abdelkhalik M, El Fouani A, Allakiss N, Mattar L, Faour W
Heliyon. 2025; 10(22):e40217.
PMID: 39748958
PMC: 11693890.
DOI: 10.1016/j.heliyon.2024.e40217.
Effect of fatty liver disease on liver function and fibrosis in patients with chronic hepatitis B: a cross-sectional study.
Fang X, Yin Y, Zhao H, Wang C, Li H, Shang Y
Front Med (Lausanne). 2024; 11:1481051.
PMID: 39640976
PMC: 11617145.
DOI: 10.3389/fmed.2024.1481051.
Metabolic Dysfunction-Associated Steatotic Liver Disease in Type 2 Diabetes Mellitus: A Review and Position Statement of the Fatty Liver Research Group of the Korean Diabetes Association.
Bae J, Han E, Lee H, Park C, Chung C, Lee D
Diabetes Metab J. 2024; 48(6):1015-1028.
PMID: 39610131
PMC: 11621661.
DOI: 10.4093/dmj.2024.0541.
Protective Effect of High Adherence to Mediterranean Diet on the Risk of Incident Type-2 Diabetes in Subjects with MAFLD: The Di@bet.es Study.
Lago-Sampedro A, Oualla-Bachiri W, Garcia-Serrano S, Maldonado-Araque C, Valdes S, Doulatram-Gamgaram V
Nutrients. 2024; 16(21).
PMID: 39519621
PMC: 11548257.
DOI: 10.3390/nu16213788.
Comparative associations of non-alcoholic fatty liver disease and metabolic dysfunction-associated steatotic liver disease with risk of incident chronic kidney disease: a cohort study.
Heo J, Lee M, Kim S, Zheng M, Byrne C, Targher G
Hepatobiliary Surg Nutr. 2024; 13(5):801-813.
PMID: 39507738
PMC: 11534778.
DOI: 10.21037/hbsn-23-558.
Metabolic-Associated Fatty Liver Disease: The Influence of Oxidative Stress, Inflammation, Mitochondrial Dysfunctions, and the Role of Polyphenols.
Tauil R, Golono P, de Lima E, de Alvares Goulart R, Landgraf Guiguer E, Bechara M
Pharmaceuticals (Basel). 2024; 17(10).
PMID: 39458995
PMC: 11510109.
DOI: 10.3390/ph17101354.
Clinical characteristics of lean metabolic-associated fatty liver disease and the impact of concurrent diabetes mellitus.
Cheng Y, Wang S, Wang C, Kao J
Tzu Chi Med J. 2024; 36(4):425-432.
PMID: 39421499
PMC: 11483085.
DOI: 10.4103/tcmj.tcmj_253_23.
Metabolic (dysfunction)-associated fatty liver disease metrics and contributions to liver research.
Suoh M, Esmaili S, Eslam M, George J
Hepatol Int. 2024; 18(6):1740-1755.
PMID: 39412611
PMC: 11632019.
DOI: 10.1007/s12072-024-10731-0.
Overlapping group between non-alcoholic fatty liver disease and metabolic associated fatty liver disease better for liver research.
Cheng Y, Hsieh T, Wang C, Kao J
JGH Open. 2024; 8(10).
PMID: 39403113
PMC: 11471878.
DOI: 10.1002/jgh3.70039.
Converging Pathways between Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and Diabetes in Children.
Faienza M, Farella I, Khalil M, Portincasa P
Int J Mol Sci. 2024; 25(18).
PMID: 39337412
PMC: 11432101.
DOI: 10.3390/ijms25189924.
Genomic insight into COVID-19 severity in MAFLD patients: a single-center prospective cohort study.
Buchynskyi M, Oksenych V, Kamyshna I, Budarna O, Halabitska I, Petakh P
Front Genet. 2024; 15:1460318.
PMID: 39296547
PMC: 11408174.
DOI: 10.3389/fgene.2024.1460318.
Synergistic effects of glucose tolerance and BMI on cardiovascular events and all-cause mortality in a healthy population: CA.ME.LI.A study 7 years follow-up.
Bignotto M, Bianco E, Centofanti L, Russo A, Cas M, Zermiani P
Am J Physiol Endocrinol Metab. 2024; 327(4):E498-E511.
PMID: 39196799
PMC: 11482241.
DOI: 10.1152/ajpendo.00181.2024.
Machine learning based identification potential feature genes for prediction of drug efficacy in nonalcoholic steatohepatitis animal model.
Matboli M, Abdelbaky I, Khaled A, Khaled R, Hamady S, Farid L
Lipids Health Dis. 2024; 23(1):266.
PMID: 39182075
PMC: 11344433.
DOI: 10.1186/s12944-024-02231-9.
Bidirectional relationship between infection and nonalcoholic fatty liver disease: insights from a comprehensive meta-analysis.
Zhang D, Wang Q, Bai F
Front Nutr. 2024; 11:1410543.
PMID: 39161913
PMC: 11332609.
DOI: 10.3389/fnut.2024.1410543.
